The Schmitt family is grateful for the resources through A-T Children’s Project, as well as the love and care at St. Jude’s, ...

Quince Therapeutics, Inc. (Nasdaq: QNCX) is a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases. For more information on ...

Quince Therapeutics (QNCX) “announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for U.S. Patent Application ...

This repeated growth didn’t have much effect on the patients until the gene mutated in size to more than 150 repeats. At this point, other genes that are normally turned off in SPNs begin to ...

This new option validates our combination approach to improve outcomes for patients living with advanced KRAS G12C-mutated metastatic colorectal cancer." The CodeBreaK 300 clinical trial compared ...

The combination treatment specifically targets KRAS-mutated metastatic colorectal cancer (CRC) to improve progression-free survival. The approval was based on results from CodeBreaK 300 ...

In the summer of 1977, Yosef Shiloh, then a graduate student, visited an Israeli Moroccan Jewish family with several children affected by ataxia-telangiectasia (A-T ... ATM (A-T, mutated). The gene ...

Abuhelwa Z, Ali NHA, Xie Z, et al. The argument for targeted therapy in IDH1 mutated myelodysplastic syndromes (MDS): poor outcomes post-hypomethylating agent failure in higher risk MDS and ...

“Treating advanced EGFR-mutated non-small cell lung cancer presents a significant challenge due to the limited efficacy of available treatments once the disease has progressed following front-line ...